CRO Alliance Pharma’s Executive Team Grows by Four, Supporting Bioanalytical, DMPK and CMC Testing Expansions

September 21, 2022 8:00 AM / by Alliance Pharma

C SuiteMALVERN, Pa.; Sept. 21, 2022 (Business Wire) – Alliance Pharma (Alliance), a global leader in bioanalytical, DMPK and CMC testing services in the pharmaceutical and biopharmaceutical industry, has grown their leadership team by four, bringing onboard a new Chief Operating Officer (COO), Chief Commercial Officer (CCO), Chief Financial Officer (CFO), and Chief People Officer (CPO). These leaders will support continued global expansion, which includes Alliance’s recent acquisition of U.K.-based Drug Development Solutions (DDS) from LGC and new bioanalytical laboratory opening in Australia in November.


U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia

MALVERN, Pa. and BRISBANE, Australia; Aug. 11, 2022 – Alliance Pharma (Alliance), a global leader in bioanalytical and CMC testing services in the pharmaceutical and biopharmaceutical industry, today announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.

Alliance Pharma Pty, Ltd. will contain an expansive state-of-the-art lab, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will . . .


U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business

Expands bioanalytical services to include many emerging areas worldwide

Merge_png_small4MALVERN, Pa.; July 13, 2022 (Business Wire) – Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company.



AlliancePharma Announces Launch of Professional Services Quoting Application, PSQuote from CLD Partners

 Apr 29, 2022 3:57:19 PM / by Alliance Pharma

MALVERN, Pa., April 29, 2022 /PRNewswire/ -- logo@2x_CLDThis week, AlliancePharma (Malvern, PA) announced their go-live of PSQuote together with CLD Partners (Front Royal, VA). PSQuote is a newly developed professional services quoting application built on the Salesforce platform (PSQuote is a wholly-owned division of CLD Partners). AlliancePharma will use the tool to enhance and elevate their sales cycle, delivering a better customer sales experience--from quote to service delivery. CLD Partners has engaged with AlliancePharma since June 2021, for FinancialForce implementation services, and this new deployment is the next step in a growing business relationship. . . 


Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer

Apr 12, 2022 4:51:57 PM / by Alliance Pharma 

Alliance_Pat__Announce1pngMalvern, PA, March 25, 2022 - Alliance Pharma, a leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, announces that Patrick Bennett has been named Chief Executive Officer. Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and . . . 


Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO

Nov 19, 2021 10:23:36 AM / by Alliance Pharma 

logo_ampersandWELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, cell and gene therapy, and protein characterization assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.